IC 005. US 005 006 018 044 046 051 052. G & S: Biological preparations for gene therapy; Biological preparations for treatment of neurological diseases and disorders; gene therapy preparations for treatment of disease, namely, Parkinson's disease, Huntington's disease, Friedreich's ataxia, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, tauopathies, synucleinopathies, and neurodegenerative disease; treatments for neurological diseases via gene replacement, gene knockdown, or vectorized antibodies, namely, Parkinson's disease, Huntington's disease, Friedreich's ataxia, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, tauopathies, synucleinopathies, and neurodegenerative disease; gene therapy preparations for neurological diseases, namely, frontotemporal lobar degeneration (FTD), Pick's disease, progressive supranuclear palsy (PSP), and corticobasal degeneration
IC 042. US 100 101. G & S: Biotechnology research services; research and development of platform technologies for genetic delivery of therapies and pharmaceuticals; research, development, and collaboration services in the field of platforms technologies for genetic delivery of therapies and pharmaceuticals; research and development in the pharmaceutical and biotechnology fields; research and development regarding the use of RNA-based functional screening platforms to discover, research and develop novel capsids for genetic deliver of therapies and pharmaceuticals
International Codes: | 5 |
U.S. Codes: | 005,006,018,044,046,051,052 |
International Codes: | 42 |
U.S. Codes: | 100,101 |
International Codes: | 44 |
U.S. Codes: | 100,101 |
Type Code | Type |
---|
GS0051 | Biological preparations for gene therapy; Biological preparations for treatment of neurological diseases and disorders; gene therapy preparations for treatment of disease, namely, Parkinson's disease, Huntington's disease, Friedreich's ataxia, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, tauopathies, synucleinopathies, and neurodegenerative disease; treatments for neurological diseases via gene replacement, gene knockdown, or vectorized antibodies, namely, Parkinson's disease, Huntington's disease, Friedreich's ataxia, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, tauopathies, synucleinopathies, and neurodegenerative disease; gene therapy preparations for neurological diseases, namely, frontotemporal lobar degeneration (FTD), Pick's disease, progressive supranuclear palsy (PSP), and corticobasal degeneration |